Challenges in the management of asthma associated with smoking-induced airway diseases

References

• Reitsma MB, Fullman N, Ng M, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the global burden of disease study 2015. Lancet. 2017;389(10082):1885–1906.
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2018 [cited 2018 Apr 7]; Available from: http://www.goldcopd.org
   Google Scholar
• Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med. 2015;175(9):1539–1549.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. New Engl J Med. 2016;374(19):1811–1821.
   PubMed Web of Science ®Google Scholar
• To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):204.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Asthma and smoking-induced airway disease without spirometric COPD. Eur Respir J. 2017;49:5.
   Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA) 2018 [cited 2018 Apr 7]; Available from: http://www.ginasthma.org/
   Google Scholar
• Kumbhare S, Pleasants R, Ohar JA, et al. Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States. Annals ATS. 2016;13(6):803–810.
   Google Scholar
• Bateman ED, Reddel HK, van Zyl-Smit RN, et al. The asthma–COPD overlap syndrome: towards a revised taxonomy of chronic airways diseases? Lancet Respir Med. 2015;3(9):719–728.
   PubMed Web of Science ®Google Scholar
• Çolak Y, Afzal S, Nordestgaard BG, et al. Characteristics and prognosis of never-smokers and smokers with asthma in the copenhagen general population study. A prospective cohort study. Am J Resp Crit Care Med. 2015;192(2):172–181.
   PubMed Web of Science ®Google Scholar
• Thomson NC, Spears M. Asthma guidelines and smokers: it’s time to be inclusive. Chest. 2012;141(2):286–288.
   PubMed Web of Science ®Google Scholar
• Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–223.
   PubMed Web of Science ®Google Scholar
• Atkins D, Best D, Briss P, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Addressing corticosteroid insensitivity in adults with asthma. Expert Rev Respir Med. 2016;10(2):137–156.
   PubMed Web of Science ®Google Scholar
• Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230.
   PubMed Web of Science ®Google Scholar
• Tomlinson JEM, McMahon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60(4):282–287.
   PubMed Web of Science ®Google Scholar
• Telenga E, Kerstjens H, Ten Hacken N, et al. Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. BMC Pulm Med. 2013;13(1):58.
   PubMed Web of Science ®Google Scholar
• Cahn A, Boyce M, Mistry S, et al. Randomised trial of allergen-induced asthmatic response in smokers and non-smokers: effects of inhaled corticosteroids. Clin Exp Allergy. 2015;45(10):1531–1541.
   PubMed Web of Science ®Google Scholar
• Pedersen SE, Bateman ED, Bousquet J, et al. Determinants of response to fluticasone propionate and salmeterol/fluticasone propionate combination in the gaining optimal asthma control study. J Allergy Clin Immunol. 2007;120(5):1036–1042.
   PubMed Web of Science ®Google Scholar
• Dijkstra A, Vonk JM, Jongepier H, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax. 2006;61(2):105–110.
   PubMed Web of Science ®Google Scholar
• Lange P, Scharling H, Ulrik CS, et al. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax. 2006;61(2):100–104.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Lamm CJ, Busse WW, et al. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest. 2009;136(6):1514–1520.
   PubMed Web of Science ®Google Scholar
• Zheng X, Guan W, Zheng J, et al. Smoking influences response to inhaled corticosteroids in patients with asthma: a meta-analysis. Curr Med Res Opin. 2012;28(11):1791–1798.
   PubMed Web of Science ®Google Scholar
• Hayes CE, Nuss HJ, Tseng T-S, et al. Use of asthma control indicators in measuring inhaled corticosteroid effectiveness in asthmatic smokers: a systematic review. J Asthma. 2015;52(10):996–1005.
   PubMed Web of Science ®Google Scholar
• Shimoda T, Obase Y, Kishikawa R, et al. Influence of cigarette smoking on airway inflammation and inhaled corticosteroid treatment in patients with asthma. Allergy Asthma Proc: Off J Reg State Allergy Soc. 2016;37(4):e50–e58.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Santini G, et al. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014;19(12): 1928–1935. 2014/12/01/.
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Komatsu Y, Fujimoto K, et al. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283–289.
   PubMed Web of Science ®Google Scholar
• Feng J-X, Lin Y, Lin J, et al. Relationship between fractional exhaled nitric oxide level and efficacy of inhaled corticosteroid in asthma-COPD overlap syndrome patients with different disease severity. J Korean Med Sci. 2017;32(3):439–447.
   PubMed Web of Science ®Google Scholar
• Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol. 2015;136(3):601–609.
   PubMed Web of Science ®Google Scholar
• Lim HS, Choi SM, Lee J, et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Annals Allergy Asthma Immunol. 2014;113(6):652–657.
   PubMed Web of Science ®Google Scholar
• Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap: clinical relevance of genomic signatures of type 2 Inflammation in COPD. Am J Resp Crit Care Med. 2015;191(7):758–766.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Anderson JA, Brook RD, et al. Cigarette smoking and response to inhaled corticosteroids in COPD. Eur Respir J. 2018;51:1.
   Web of Science ®Google Scholar
• Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8):783–790.
   PubMed Web of Science ®Google Scholar
• Roche N, Postma DS, Colice G, et al. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. Am J Resp Crit Care Med. 2015;191(8):960–964.
   PubMed Web of Science ®Google Scholar
• Cox CA, Boudewijn IM, Vroegop SJ, et al. Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma. Respir Med. 2017;130:35–42.
   PubMed Web of Science ®Google Scholar
• Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174(2):127–133.
   PubMed Web of Science ®Google Scholar
• Livingston E, Chaudhuri R, McMahon AD, et al. Systemic sensitivity to corticosteroids in smokers with asthma. Eur Respir J. 2007;29(1):64–71.
   PubMed Web of Science ®Google Scholar
• Spears M, McSharry C, Chaudhuri R, et al. Smoking in asthma is associated with elevated levels of corticosteroid resistant sputum cytokines-an exploratory study. PLoS One. 2013;8(8):e71460.
   PubMed Web of Science ®Google Scholar
• Gershon AS, Campitelli MA, Croxford R, et al. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312(11):1114–1121.
   PubMed Web of Science ®Google Scholar
• Clearie KL, McKinlay L, Williamson PA, et al. Fluticasone/salmeterol combination confers benefits in people with asthma who smoke. Chest. 2012;141(2):330–338.
   PubMed Web of Science ®Google Scholar
• Pilcher J, Patel M, Reddel HK, et al. Effect of smoking status on the efficacy of the SMART regimen in high risk asthma. Respirology. 2016;21(5):858–866.
   PubMedGoogle Scholar
• van Schayck OCP, Haughney J, Aubier M, et al. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study. Respir Med. 2012;106(2):189–196.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial. Lancet. 2017;390(10109):2247–2255.
   PubMed Web of Science ®Google Scholar
• Ishiura Y, Fujimura M, Shiba Y, et al. A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome. Pulm Pharm Therap. 2015;35:28–33.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Tada Y, Kawata N, et al. Clinical, physiological, and radiological features of asthma–chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2015;10:947–954.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Park HY, Kim EK, et al. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma–COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2797–2803.
   PubMed Web of Science ®Google Scholar
• Su VY-F, Yang K-Y, Yang Y-H, et al. Use of ICS/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma. J Allergy Clin Immunol in Pract. 2018 Feb 10. pii: S2213–2198(18)30090–4. In press.
   PubMedGoogle Scholar
• Brusselle G, Peché R, Van den Brande P, et al. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status. Respir Med. 2012;106(6):811–819.
   PubMed Web of Science ®Google Scholar
• Contoli M, Bellini F, Morandi L, et al. Assessing small airway impairment in mild-to-moderate smoking asthmatic patients. Eur Respir J. 2016;47(4):1264–1267.
   PubMed Web of Science ®Google Scholar
• Marth K, Spinola M, Kisiel J, et al. Treatment response according to small airway phenotypes: a real-life observational study. Therap Adv Respir Dis. 2016;10(3):200–210.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015 [2015 May 28];58(10):4131–4164.
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. 2018 [cited 2018 Apr 7]; Available from: https://clinicaltrials.gov/
   Google Scholar
• Kerstjens HAM, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Kew K, Karen D. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;(1). Art. No.: CD011721. DOI:10.1002/14651858.CD011721.pub2.
   Web of Science ®Google Scholar
• Thomson NC. New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma. Expert Opin Pharmacother. 2017;18(3):283–293.
   PubMed Web of Science ®Google Scholar
• Kerstjens HAM, Moroni-Zentgraf P, Tashkin DP, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med. 2016;117:198–206.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kaneko Y, Ishimatsu A, et al. Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. Pulm Pharmacol Ther. 2017;42:7–12.
   PubMed Web of Science ®Google Scholar
• Price D, Kaplan A, Jones R, et al. Long-acting muscarinic antagonist use in adults with asthma: real-life prescribing and outcomes of add-on therapy with tiotropium bromide. J Asthma Allergy. 2015;8:1–13.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Bugnas B, van Noord J, et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med. 2008;102(1):50–56.
   PubMed Web of Science ®Google Scholar
• Yoshida M, Nakano T, Fukuyama S, et al. Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. Pulm Pharm Therap. 2013;26(2):159–166.
   PubMed Web of Science ®Google Scholar
• McGarvey L, Morice AH, Smith JA, et al. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials. BMJ Open Respir Res. 2016;3:1.
   Web of Science ®Google Scholar
• Thomson NC, Chaudhuri R, Messow CM, et al. Chronic cough and sputum production are associated with worse clinical outcomes in stable asthma. Respir Med. 2013;107(10):1501–1508.
   PubMed Web of Science ®Google Scholar
• Wurst KE, Rheault TR, Edwards L, et al. A comparison of COPD patients with and without ACOS in the ECLIPSE study. Eur Respir J. 2016;47:1559–1562.
   PubMed Web of Science ®Google Scholar
• Thomson NC, Chaudhuri R, Spears M, et al. Arachidonic acid metabolites and enzyme transcripts in asthma are altered by cigarette smoking. Allergy. 2014;69(4):527–536.
   PubMed Web of Science ®Google Scholar
• Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011;364(18):1695–1707.
   PubMed Web of Science ®Google Scholar
• Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131(3):763–771.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Role of HDAC2 in the Pathophysiology of COPD. Annu Rev Physiol. 2009;71(1):451–464.
   PubMed Web of Science ®Google Scholar
• Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J. 2009;33(5):1010–1017.
   PubMed Web of Science ®Google Scholar
• Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J. 2010;36(3):646–654.
   PubMed Web of Science ®Google Scholar
• Cameron EJ, McSharry C, Chaudhuri R, et al. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012;42(9):1302–1312.
   PubMed Web of Science ®Google Scholar
• Hao M, Lin J, Shu J, et al. Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2. J Thorac Dis. 2015;7(7):1189–1197.
   PubMed Web of Science ®Google Scholar
• Kew K, Undela K, Kotorts I, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2015;15(9):CD002997.
   Google Scholar
• Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668.
   PubMed Web of Science ®Google Scholar
• Cameron EJ, Chaudhuri R, Mair F, et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J. 2013;42(5):1412–1415.
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Resir Crit Care Med. 2014;189(12):1503–1508.
   PubMed Web of Science ®Google Scholar
• Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochim Biophys Acta. 2012;1822(5):714–728.
   PubMed Web of Science ®Google Scholar
• Jesenak M, Zelieskova M, Babusikova E. Oxidative stress and bronchial asthma in children—causes or consequences? Front Pediatr. 2017;5:162.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24(137):451–461.
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur Respir J. 2017;50:4.
   Web of Science ®Google Scholar
• Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015 7.
   Web of Science ®Google Scholar
• Thomson NC. Targeting oxidant-dependent mechanisms for the treatment of respiratory diseases and their comorbidities. Curr Opin Pharmacol. 2018;40:1–8.
   PubMed Web of Science ®Google Scholar
• Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12(3):275–286.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bousquet J, Aubier M, et al. Roflumilast for asthma: efficacy findings in non-placebo-controlled comparator and dosing studies. Pulm Pharm. 2015;35(Suppl):S11–9.
   Google Scholar
• Meltzer EO, Chervinsky P, Busse W, et al. Roflumilast for asthma: efficacy findings in placebo-controlled studies. Pulm Pharm Therap. 2015;35(Suppl):S20–S27.
   PubMedGoogle Scholar
• Bateman ED, Goehring U-M, Richard F, et al. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. J Allergy Clin Immunol. 2016;138(1):142–49.e8.
   PubMed Web of Science ®Google Scholar
• Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729–734.
   PubMed Web of Science ®Google Scholar
• Yeganeh B, Wiechec E, Ande S, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143(1):87–110.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Clinical studies of statins in asthma and COPD. Curr Mol Pharmacol. 2017;10(1):60–71.
   PubMed Web of Science ®Google Scholar
• Braganza G, Chaudhuri R, McSharry C, et al. Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial. BMC Pulm Med. 2011;11:16.
   PubMed Web of Science ®Google Scholar
• Thomson NC, Charron CE, Chaudhuri R, et al. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther. 2015;31(4):1–8.
   PubMedGoogle Scholar
• Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, et al. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126(4):754–762.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin suppresses airway IL-17 and upregulates IL-10 in patients with stable COPD. Chest. 2015;148(5):1164–1176.
   PubMed Web of Science ®Google Scholar
• Zeki AA, Elbadawi-Sidhu M. Innovations in asthma therapy: is there a role for inhaled statins? Exp Rev Respir Med. 2018 Mar 26. null-null. DOI:10.1080/17476348.2018.1457437
   PubMed Web of Science ®Google Scholar
• Jiménez-Ruiz CA, Andreas S, Lewis KE, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J. 2015;46(1):61–79.
   PubMed Web of Science ®Google Scholar
• To T, Daly C, Feldman R, et al. Results from a community-based program evaluating the effect of changing smoking status on asthma symptom control. BMC Public Health. 2012;12(1):293.
   PubMedGoogle Scholar
• Tonnesen P, Pisinger C, Hvidberg S, et al. Effects of smoking cessation and reduction in asthmatics. Nicotine Tob Res. 2005;7(1):139–148.
   PubMed Web of Science ®Google Scholar
• Westergaard CG, Porsbjerg C, Backer V. The effect of smoking cessation on airway inflammation in young asthma patients. Clin Exp Allergy. 2014;44(3):353–361.
   PubMed Web of Science ®Google Scholar
• Jang A-S, Park S-W, Kim D-J, et al. Effects of smoking cessation on airflow obstruction and quality of life in asthmatic smokers. Allergy Asthma Immunol Res. 2010;2(4):254–259.
   PubMed Web of Science ®Google Scholar
• Boulet L, FitzGerald J, McIvor R, et al. Influence of current or former smoking on asthma management and control. Can Respir J. 2008;15(5):275–279.
   PubMed Web of Science ®Google Scholar
• Clatworthy J, Price D, Ryan D, et al. The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control. Prim Care Resp J. 2009;18(4):300–305.
   PubMedGoogle Scholar
• Thomson NC, Chaudhuri R, Heaney LG, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol. 2013;131(4):1008–1016.
   PubMed Web of Science ®Google Scholar
• Maltby S, Gibson PG, Powell H, et al. Omalizumab treatment response in a population with severe allergic asthma and overlapping COPD. Chest. 2017;151(1):78–89.
   PubMed Web of Science ®Google Scholar
• Tat TS, Cilli A. Omalizumab treatment in asthma-COPD overlap syndrome. J Asthma. 2016;53(10):1048–1050.
   PubMed Web of Science ®Google Scholar
• Yalcin AD, Celik B, Yalcin AN. Omalizumab (anti-IgE) therapy in the asthma–COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels. Immunopharmacol Immunotoxicol. 2016;38(3):253–256.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Milanese M, et al. Factors reducing omalizumab response in severe asthma. Eur J Intern Med. 2018 Jan 29;52:78–85.
   PubMed Web of Science ®Google Scholar
• Cosío BG, Pérez de Llano L, Lopez Viña A, et al. Th-2 signature in chronic airway diseases: towards the extinction of asthma−COPD overlap syndrome? Eur Respir J. 2017;49(5).
   Web of Science ®Google Scholar
• Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349.
   PubMed Web of Science ®Google Scholar
• Yancey S, Albers F, Gunsoy N, et al. Effect of mepolizumab on exacerbations in asthma patients with features common in COPD. Am J Resir Crit Care Med. 2017;195:A4683–A83.
   Web of Science ®Google Scholar
• Wenzel SE, Jayawardena S, Graham NMH, et al. Severe asthma and asthma-chronic obstructive pulmonary disease syndrome: authors’ reply. Lancet. 2016;388(10061):2742.
   PubMed Web of Science ®Google Scholar
• Gross NJ, Barnes PJ. New therapies for asthma and chronic obstructive pulmonary disease. Am J Resir Crit Care Med. 2017;195(2):159–166.
   PubMed Web of Science ®Google Scholar
• Fabbri LM. Smoking, not COPD, as the disease. N Eng J Med. 2016;374(19):1885–1886.
   PubMed Web of Science ®Google Scholar
• Thomson NC. Respiratory symptoms and small airway dysfunction in current and former smokers without spirometric COPD. Respirology. 2018;23(5):446–447.
   PubMed Web of Science ®Google Scholar
• Agustí A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017;50:4.
   Web of Science ®Google Scholar